Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

VolitionRx

MCap

USD76m

Last close

USD0.81

▲ 0.14 (20.90%)

Canyon Resources

MCap

AUD262m

Last close

AUD0.19

▲ 0.02 (12.12%)

Immix Biopharma

MCap

USD51m

Last close

USD1.82

▲ 0.12 (7.06%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Ultimovacs – executive interview

Ultimovacs – executive interview

Ultimovacs — 7 videos in collection

More on this equity

Ultimovacs is a Scandinavian-based biotech focused on developing novel immunotherapies in combination with checkpoint inhibitors against cancer. Its lead product candidate, UV1, is a universal off-the-shelf peptide-based vaccine being studied in ongoing Phase II clinical trials across five indications. The innovative oncology vaccine targets the cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has broad potential in a variety of settings and would increase accessibility.

In this interview, Ultimovacs CMO Jens Bjørheim recaps the company’s progress and provides a preview of the upcoming rich newsflow.

< Previous

Next >

You may also be interested in these:

Healthcare

27.02.24

Ultimovacs – executive interview

Healthcare

21.10.22

Ultimovacs - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free